BMC Cancer (Feb 2012)

Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells

  • Acuña Sanhueza Gustavo A,
  • Faller Leonie,
  • George Babitha,
  • Koffler Jennifer,
  • Misetic Vinko,
  • Flechtenmacher Christa,
  • Dyckhoff Gerhard,
  • Plinkert Peter P,
  • Angel Peter,
  • Simon Christian,
  • Hess Jochen

DOI
https://doi.org/10.1186/1471-2407-12-72
Journal volume & issue
Vol. 12, no. 1
p. 72

Abstract

Read online

Abstract Background Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent and lethal cancers worldwide and mortality mostly results from loco-regional recurrence and metastasis. Despite its significance, our knowledge on molecular, cellular and environmental mechanisms that drive disease pathogenesis remains largely elusive, and there are limited therapeutic options, with only negligible clinical benefit. Methods We applied global gene expression profiling with samples derived from a recently established mouse model for oral cancer recurrence and identified a list of genes with differential expression between primary and recurrent tumors. Results One differentially expressed gene codes for Myb-binding protein 1a (MYBBP1A), which is known as a transcriptional co-regulator that physically interacts with nuclear transcription factors, such as NFκB and p53. We confirmed significantly reduced MYBBP1A protein levels on tissue sections of recurrent mouse tumors compared to primary tumors by immunohistochemistry, and found aberrant MYBBP1A protein levels also in tumor samples of HNSCC patients. Interestingly, silencing of MYBBP1A expression in murine SCC7 and in human HNSCC cell lines elicited increased migration but decreased cell growth. Conclusion We provide experimental evidence that MYBBP1A is an important molecular switch in the regulation of tumor cell proliferation versus migration in HNSCC and it will be a major challenge for the future to proof the concept whether regulation MYBBP1A expression and/or function could serve as a novel option for anti-cancer therapy.